SCYNEXIS, Inc. (SCYX) |
| 3.77 -0.09 (-2.33%) 10-30 16:00 |
| Open: | 3.74 |
| High: | 3.885 |
| Low: | 3.695 |
| Volume: | 117,765 |
| Market Cap: | 24(M) |
| PE Ratio: | -1.1 |
| Exchange: | NASDAQ |
| Industry: | Medical - Pharmaceuticals |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 5.51 |
| Resistance 1: | 4.76 |
| Pivot price: | 3.84 |
| Support 1: | 3.54 |
| Support 2: | 2.94 |
| 52w High: | 9.12 |
| 52w Low: | 3.53 |
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Financials
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | -78.113 |
| Profit Margin (%) | -53.26 |
| Operating Margin (%) | -3.00 |
| Return on Assets (ttm) | 308.5 |
| Return on Equity (ttm) | -20.8 |
Company news
Thu, 29 Oct 2026
A live webcast will feature SCYNEXIS leaders on Nov. 9 - Stock Titan
Thu, 22 Oct 2026
SCYNEXIS (NasdaqCM:SCYX) Stock Forecast & Analyst Predictions - Simply Wall Street
Tue, 22 Sep 2026
Scynexis (NASDAQ: SCYX) adds kidney drug specialist to its board - Stock Titan
Sun, 20 Sep 2026
SCYNEXIS (SCYX) Holds Steady at $4.46 as Traders Eye $4.68 Resistance - Standard Deviation - https://www.dars.gov.et/
Sat, 25 Jul 2026
SCYNEXIS, Inc. Revenue Breakdown – NASDAQ:SCYX - TradingView
Thu, 25 Jun 2026
SCYX Forecast — Price Target — Prediction for 2027 - TradingView
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
